Robert B. Den, MD
About 90% of patients with prostate cancer who develop metastases will develop growths in the bone, says Robert B. Den, MD. These bone metastases can severely impact a patient’s quality of life, so finding the right bone-targeting agents is imperative, he adds.
State of the Science Summit™ on Prostate Cancer, Den, an associate professor of radiation oncology at Thomas Jefferson University Hospital, discussed bone-targeting agents in prostate cancer. In an interview during the meeting, Den explained where the landscape currently stands with bone-targeting agents, and the potential future of combinations and novel strategies.
OncLive: Can you provide an overview on your lecture of bone-targeting agents in prostate cancer?
Prostate cancer is a unique malignancy in that it tends to have a preponderance of metastases to the bone. Bone metastases can impact a patient’s quality of life by causing severe bone pain, so this is an area where we have begun thinking about targeting the bone microenvironment specifically, in a sort of tumor agnostic way.
... to read the full story